Sirnaomics Names China Partner for siRNA Therapeutic
June 23, 2011 at 07:11 AM EDT
Sirnaomics, located in Maryland, USA, has partnered with Guangdong Zhongsheng Pharmaceutical Co. to develop its small interfering RNA (siRNA) ocular neovascularization therapeutic. The partnership will seek to develop and commercialize STP601, a Sirnaomics siRNA candidate for treatment of diabetic retinopathy and age-related macular degeneration. Zhongsheng Pharma is committing 63 million RMB ($9.8 million) to the partnership, including upfront and milestone payments. More details.... Stock Symbol: (SZE: 002317) Share this with colleagues: